祥生医疗(688358) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥101,893,743.14, representing a year-on-year increase of 14.73%[5] - The net profit attributable to shareholders for the same period was ¥30,592,683.67, reflecting a growth of 14.82% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥29,267,285.58, which increased by 24.03% year-on-year[5] - Total operating revenue for the first three quarters of 2021 reached ¥288,630,736.15, an increase of 32% compared to ¥218,731,971.61 in the same period of 2020[20] - Net profit for the first three quarters of 2021 was ¥77,775,013.19, representing a 18% increase from ¥65,820,787.23 in the same period of 2020[21] - Basic and diluted earnings per share for the third quarter of 2021 were both ¥0.97, compared to ¥0.82 in the same quarter of 2020[22] - The company reported a profit before tax of ¥84,196,566.16 for the first three quarters of 2021, compared to ¥77,614,333.93 in the same period of 2020[21] Research and Development - Research and development expenses totaled ¥19,029,716.95 in Q3 2021, up 53.03% from the same period last year[6] - The R&D expenditure accounted for 18.68% of operating revenue, an increase of 4.68 percentage points compared to the previous year[6] - Research and development expenses for the first three quarters of 2021 amounted to ¥49,822,013.70, up from ¥40,456,243.81 in the previous year[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,341,023,361.19, a decrease of 0.64% from the end of the previous year[6] - The total current assets as of September 30, 2021, amounted to ¥1,230,509,429.58, a decrease from ¥1,270,654,721.04 at the end of 2020[16] - The total assets of the company were reported at ¥1,341,023,361.19, slightly down from ¥1,349,604,046.26[17] - The company reported a total of ¥933,396,538.42 in capital reserves, indicating a solid financial foundation[28] - The total liabilities decreased to ¥127,904,189.38 from ¥156,698,950.83 year-over-year[19] - Total liabilities amounted to ¥156,698,950.83, with a slight increase of ¥1,322,367.41 compared to the previous period[28] - Current liabilities were reported at ¥129,043,028.18, showing a minor decrease compared to the previous figure[28] Cash Flow - The cash flow from operating activities showed a net outflow of ¥3,554,235.75, a decline of 79.63% compared to the previous year[6] - Cash generated from operating activities in the first three quarters of 2021 was ¥274,307,423.77, an increase from ¥231,181,812.59 in the same period of 2020[23] - The net cash inflow from operating activities was CNY 3,554,235.75, a decrease of 79.7% compared to CNY 17,450,508.76 in the previous year[24] - The total cash outflow from operating activities was CNY 304,878,490.20, compared to CNY 240,009,153.31 in the previous year, representing a 27% increase[24] - Cash and cash equivalents at the end of the period totaled CNY 768,121,630.71, an increase from CNY 175,110,083.92 at the end of the previous year[25] Shareholder Information - The company reported a total of 4,969 common shareholders at the end of the reporting period[12] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., held 32,400,000 shares, accounting for 40.50% of the total shares[12] Dividend and Tax - The company paid CNY 64,000,000.00 in dividends, down from CNY 80,000,000.00, indicating a 20% reduction in dividend payouts[25] - The company received CNY 28,469,966.57 in tax refunds, up from CNY 17,007,608.13, marking a 67.5% increase[24] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[15] - There are no significant mergers or acquisitions reported during this quarter[15] - The company has implemented the new leasing standards effective from January 1, 2021, which may impact future financial reporting[29]